Immunocore Holdings plc (NASDAQ:IMCR – Get Free Report) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 4,610,000 shares, an increase of 7.5% from the March 15th total of 4,290,000 shares. Approximately 9.5% of the company’s shares are short sold. Based on an average daily volume of 491,700 shares, the short-interest ratio is currently 9.4 days.
Immunocore Stock Performance
Immunocore stock opened at $53.37 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.80 and a quick ratio of 3.77. Immunocore has a 12 month low of $42.21 and a 12 month high of $76.98. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -46.01 and a beta of 0.89. The stock’s 50-day moving average is $64.95 and its 200-day moving average is $60.31.
Immunocore (NASDAQ:IMCR – Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.12). Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The business had revenue of $70.16 million for the quarter, compared to analysts’ expectations of $53.25 million. During the same quarter in the prior year, the firm earned ($0.63) earnings per share. Immunocore’s quarterly revenue was up 22.4% compared to the same quarter last year. Equities analysts anticipate that Immunocore will post -1.54 earnings per share for the current year.
Institutional Investors Weigh In On Immunocore
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on IMCR. Mizuho lifted their price target on shares of Immunocore from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. JPMorgan Chase & Co. boosted their price target on Immunocore from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research report on Thursday, April 11th. Canaccord Genuity Group increased their target price on Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a research report on Thursday, February 29th. Finally, Oppenheimer reissued an “outperform” rating and issued a $87.00 price target (up from $85.00) on shares of Immunocore in a research note on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $80.55.
Check Out Our Latest Analysis on IMCR
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
- Five stocks we like better than Immunocore
- How Technical Indicators Can Help You Find Oversold StocksÂ
- ASML Fires Warning Shot For Tech Investors
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Prologis Stock Leading U.S. Logistics Boom
- How to Use the MarketBeat Dividend Calculator
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.